Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, the company's Chairman and CEO, will deliver a presentation on May 20th, 2025, from 10:30 to 11:00 a.m. ET. The presentation will be accessible via webcast for interested investors and stakeholders.
Nuvectis Pharma (NASDAQ: NVCT), un'azienda biofarmaceutica in fase clinica specializzata in medicine di precisione per l'oncologia, ha annunciato la sua partecipazione al prossimo 3掳 Annuale H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, Presidente e CEO dell'azienda, terr脿 una presentazione il 20 maggio 2025, dalle 10:30 alle 11:00 ET. La presentazione sar脿 disponibile in webcast per investitori e stakeholder interessati.
Nuvectis Pharma (NASDAQ: NVCT), una compa帽铆a biofarmac茅utica en etapa cl铆nica especializada en medicamentos de precisi贸n para oncolog铆a, ha anunciado su participaci贸n en la pr贸xima 3ra Conferencia Anual de Inversores H.C. Wainwright Global BioConnect. Ron Bentsur, presidente y CEO de la empresa, realizar谩 una presentaci贸n el 20 de mayo de 2025, de 10:30 a 11:00 a.m. ET. La presentaci贸n estar谩 disponible v铆a webcast para inversores y partes interesadas.
Nuvectis Pharma (NASDAQ: NVCT)電� 鞝曤皜 鞚橅暀鞚� 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雼り皜鞓る姅 鞝�3須� 鞐半 H.C. Wainwright 旮�搿滊矊 BioConnect 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 須岇灔 瓴� CEO鞚� Ron Bentsur臧� 2025雲� 5鞗� 20鞚� 霃欕秬 響滌鞁� 旮办 鞓れ爠 10鞁� 30攵勲秬韯� 11鞁滉箤歆� 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 頃措嫻 氚滍憸電� 甏�鞁� 鞛堧姅 韴瀽鞛� 氚� 鞚错暣甏�瓿勳瀽毳� 鞙勴暣 鞗轨簮鞀ろ姼搿� 鞝滉车霅╇媹雼�.
Nuvectis Pharma (NASDAQ: NVCT), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les m茅dicaments de pr茅cision pour l'oncologie, a annonc茅 sa participation 脿 la prochaine 3e conf茅rence annuelle H.C. Wainwright Global BioConnect Investor. Ron Bentsur, pr茅sident et CEO de l'entreprise, fera une pr茅sentation le 20 mai 2025, de 10h30 脿 11h00 ET. La pr茅sentation sera accessible en webcast pour les investisseurs et parties prenantes int茅ress茅s.
Nuvectis Pharma (NASDAQ: NVCT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Pr盲zisionsmedizin in der Onkologie spezialisiert hat, hat seine Teilnahme an der bevorstehenden 3. j盲hrlichen H.C. Wainwright Global BioConnect Investorenkonferenz angek眉ndigt. Ron Bentsur, Vorsitzender und CEO des Unternehmens, wird am 20. Mai 2025 von 10:30 bis 11:00 Uhr ET eine Pr盲sentation halten. Die Pr盲sentation wird f眉r interessierte Investoren und Stakeholder per Webcast zug盲nglich sein.
- None.
- None.
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.
| Event | 3rd Annual H.C. Wainwright BioConnect Investor Conference |
| Date | May 20th, 2025 |
| Time | 10:30 鈥� 11:00 a.m. ET |
| Link | Nuvectis Pharma Presentation |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
听
Media Relations Contact
Kevin Gardner
LifeSci Advisors
听
FAQ
When is Nuvectis Pharma (NVCT) presenting at the H.C. Wainwright BioConnect Conference 2025?
Who will represent Nuvectis Pharma (NVCT) at the H.C. Wainwright Conference 2025?
What is Nuvectis Pharma's (NVCT) main business focus?
How can investors access Nuvectis Pharma's (NVCT) presentation at the H.C. Wainwright Conference?
